Quick Answer: What Is Active Surveillance?
Active surveillance is a structured monitoring program for carefully selected men with localized prostate cancer. It aims to avoid or delay treatment side effects while identifying cancer changes early enough to offer curative treatment when appropriate.
It is not simply “doing nothing.” Monitoring typically includes PSA tests, clinical reviews, prostate MRI when indicated, and repeat biopsies.
Who Is a Candidate for Active Surveillance?
Active surveillance is a standard management option for many men with low-risk localized prostate cancer. Some men with favorable intermediate-risk disease, particularly selected Grade Group 2 cases, may also be considered after careful discussion with their specialist.
Eligibility is not determined by a single PSA number. The urology team considers biopsy Grade Group, the amount of cancer in biopsy samples, MRI findings, clinical stage, PSA density, life expectancy, other illnesses and patient preferences. Certain adverse pathology patterns, including cribriform or intraductal cancer, make active surveillance less appropriate.
What Does an Active Surveillance Schedule Look Like?
| Monitoring | Typical approach |
|---|---|
| PSA blood test | At least every six months under EAU guidance |
| Clinical examination | Scheduled clinical review; EAU guidance generally recommends a digital rectal examination at least yearly, with individualization when MRI is part of follow-up |
| Prostate MRI | Used at baseline or during follow-up according to previous imaging, PSA trends and risk |
| Repeat prostate biopsy | Often every two to three years, adjusted for MRI, PSA density and prior biopsy findings |
This is an example, not an individual prescription. Follow-up protocols vary by country, guideline and patient risk. A clinician may recommend earlier tests or a different biopsy schedule. The European Association of Urology’s 2026 guidance specifies structured follow-up, including repeat biopsy with or without MRI. Some carefully selected low-risk patients with stable MRI and low, stable PSA density may be able to omit a repeat biopsy following specialist assessment.
What Changes Could Lead to Treatment?
A concerning PSA trend or a new MRI finding usually triggers further investigation—not automatic surgery or radiotherapy. Biopsy-confirmed upgrading or other meaningful progression is a key reason to reconsider active treatment. Patient preferences, age, health and ability to keep up with monitoring also matter.
Active Surveillance vs Watchful Waiting: What Is the Difference?
Active surveillance is generally offered when a man could still benefit from curative treatment if the cancer progresses. It involves scheduled tests intended to detect clinically meaningful changes.
Watchful waiting is a different approach, often considered when age, frailty or other serious health conditions mean curative treatment is unlikely to provide a net benefit. Care focuses on symptoms and quality of life, and the testing strategy is generally less intensive.
Does Active Surveillance Mean Cancer Will Spread?
Not necessarily. Many appropriately selected low-risk cancers grow slowly, and long-term outcomes in surveillance cohorts are favorable. But active surveillance carries some risk of progression, so keeping monitoring appointments is essential. No program can guarantee that progression or spread will never occur.
What About Surgery and Radiation?
If treatment becomes advisable, the options may include radiation therapy, radical prostatectomy or other approaches appropriate to the cancer stage and risk category. Each has different potential effects on urinary, bowel and sexual function. Read the existing guides on prostatectomy side effects and treatment side effects.
Questions to Ask Your Urologist
- What is my Grade Group, stage, PSA density and MRI result?
- How much cancer was found in the biopsy samples?
- Why am I a suitable—or unsuitable—candidate for surveillance?
- When are my next PSA test, MRI and biopsy due?
- What specific results would prompt further investigation or treatment?
- Who will contact me about missed tests or changed results?
Related Prostate Cancer Guides
Medical References
- European Association of Urology. 2026 Prostate Cancer Guidelines: Active Surveillance.
- European Association of Urology. Prostate Cancer Guidelines: Follow-up.
- European Association of Urology Guidelines Panel. 2026 update: screening, diagnosis and local treatment with curative intent.
Medical information notice: This article is for general education only and does not replace individualized specialist assessment. A surveillance plan must be tailored to biopsy findings, cancer risk, life expectancy and patient preferences.